虚弱与胰腺癌患者死亡率增加有关。然而，关于胰腺癌患者虚弱的患病率以及胰腺癌和虚弱患者死亡率的一些证据尚未得到彻底调查，需要澄清。对 PubMed、Scopus、Web 索引的研究进行系统回顾和荟萃分析Science 和 Embase 进行了截至 2023 年 3 月的研究，并计算了汇总患病率和相对风险 (RR) 估计值。总共纳入了 18 项研究，涉及 35,191 名胰腺癌患者。胰腺癌中虚弱的患病率为 45%（95% CI = 29-62；I2 = 99.9%；p = 0.000）。在胰腺癌患者中，虚弱与相对死亡风险增加相关（RR = 1.70；95% CI = 1.30-2.22；I2 = 84.8%，p = 0.000）。胰腺癌中虚弱的患病率很常见，并且具有显着的负相关性对胰腺癌患者生存的影响。我们的研究结果具有显着的异质性，因此在解释时需要谨慎。然而，这些发现强调了评估虚弱的重要性，这可以提供预后数据并为决策优先事项提供信息。© 2023。外科肿瘤学会。

Frailty has been associated with increased mortality among patients with pancreatic cancer. Nevertheless, several lines of evidence regarding the prevalence of frailty in patients with pancreatic cancer and mortality in patients with pancreatic cancer and frailty have not been thoroughly investigated and require clarification.A systematic review and meta-analysis of studies indexed in PubMed, Scopus, Web of Science, and Embase through March 2023 were conducted, and the pooled prevalence and relative risk (RR) estimate were calculated.A total of 18 studies containing 35,191 patients with pancreatic cancer were included. The prevalence of frailty in pancreatic cancer was 45% (95% CI = 29-62; I2 = 99.9%; p = 0.000). In patients with pancreatic cancer, frailty was associated with increased relative risk for mortality (RR = 1.70; 95% CI = 1.30-2.22; I2 = 84.8%, p = 0.000).Frailty prevalence in pancreatic cancer is common and exerts a significant negative impact on the survival of patients with pancreatic cancer. Our findings are characterized by significant heterogeneity, and caution is warranted in their interpretation. However, these findings highlight the importance of evaluating frailty, which may provide prognostic data and inform decision-making priorities.© 2023. Society of Surgical Oncology.